Literature DB >> 24520815

Naïve subset develops the most important alloreactive response among human CD4+ T lymphocytes in human leukocyte antigen-identical related setting.

Mathilde Chérel1, Bachra Choufi, Jacques Trauet, Pascale Cracco, Jean-Paul Dessaint, Ibrahim Yakoub-Agha, Myriam Labalette.   

Abstract

In longitudinal clinical studies, receiving a high percentage of allogeneic donor-derived CD4(+) CCR7(+) T cells, which include naïve and central memory subsets have been correlated with increased incidence and severity of acute GVHD. Whether naïve and central memory CD4(+) T-cell subsets contribute more or equally to alloimmune responses are still unclear in human. The aim of this study was to investigate in vitro the alloreactive response of purified naïve, central memory, and effector memory CD4(+) T-cell subsets in HLA identical setting. By coculturing monocyte-derived dendritic cells and purified CD4(+) T-cell subsets, from healthy HLA-identical male and female sibling pairs, we found that naïve CD4(+) CCR7(+) CD45RA(+) T cells developed the highest proliferative response upon stimulation by minor histocompatibility antigens and were progressively driven to produce high levels of interferon-γ, tumor necrosis factor, and interleukin-6. Comparatively, the central memory CD4(+) CCR7(+) CD45RA(neg) subset proliferated to a lower extent and produced very low amounts of pro-inflammatory cytokines while the CCR7(neg) effector memory CD4(+) subset was unresponsive. This study demonstrates the superior capacity of naïve CD4(+) T cells to mount a primary alloreactive response as compared to central memory T cells. Their proliferative response associated with a pro-inflammatory differentiation makes them potentially acute GVHD inducers. These in vitro results in line with what we have observed in clinical studies and may also lend support to approaches of partial selective T-cell depletion for GVHD prevention.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  allogeneic stem cell transplantation; alloreactivity; graft-versus-host disease; human leukocyte antigen-identical sibling; naïve T cells

Mesh:

Substances:

Year:  2014        PMID: 24520815     DOI: 10.1111/ejh.12283

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  14 in total

1.  Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.

Authors:  Alessandra Roberto; Luca Castagna; Veronica Zanon; Stefania Bramanti; Roberto Crocchiolo; James E McLaren; Sara Gandolfi; Paolo Tentorio; Barbara Sarina; Inna Timofeeva; Armando Santoro; Carmelo Carlo-Stella; Benedetto Bruno; Cristiana Carniti; Paolo Corradini; Emma Gostick; Kristin Ladell; David A Price; Mario Roederer; Domenico Mavilio; Enrico Lugli
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

2.  HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.

Authors:  W Herr; Y Eichinger; J Beshay; A Bloetz; S Vatter; C Mirbeth; E Distler; U F Hartwig; S Thomas
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

3.  TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.

Authors:  Eleni Kotsiou; Jessica Okosun; Caroline Besley; Sameena Iqbal; Janet Matthews; Jude Fitzgibbon; John G Gribben; Jeffrey K Davies
Journal:  Blood       Date:  2016-04-21       Impact factor: 22.113

Review 4.  Recent advances in treatment of severe primary immunodeficiencies.

Authors:  Andrew Gennery
Journal:  F1000Res       Date:  2015-12-16

5.  Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing.

Authors:  Esteban Arrieta-Bolaños; Pietro Crivello; Maximilian Metzing; Thuja Meurer; Müberra Ahci; Julie Rytlewski; Marissa Vignali; Erik Yusko; Peter van Balen; Peter A Horn; J H Frederik Falkenburg; Katharina Fleischhauer
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

6.  Selective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression.

Authors:  Szilvia Bak; Sabine Tischer; Anna Dragon; Sarina Ravens; Lars Pape; Christian Koenecke; Mathias Oelke; Rainer Blasczyk; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Front Immunol       Date:  2018-12-17       Impact factor: 7.561

7.  Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity.

Authors:  W K Chan; D Suwannasaen; R E Throm; Y Li; P W Eldridge; J Houston; J T Gray; C-H Pui; W Leung
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

8.  ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.

Authors:  Denis Claude Roy; Irwin Walker; Johan Maertens; Philippe Lewalle; Eduardo Olavarria; Dominik Selleslag; Sylvie Lachance; Marc Buyse; Kun Wang; Jeroen Rovers; Irene Santi; Halvard Bonig; Andrew Sandler; Jurjen Velthuis; Stephan Mielke
Journal:  Leukemia       Date:  2020-02-11       Impact factor: 11.528

9.  Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation.

Authors:  Thuja Meurer; Esteban Arrieta-Bolaños; Maximilian Metzing; Mona-May Langer; Peter van Balen; J H Frederik Falkenburg; Dietrich W Beelen; Peter A Horn; Katharina Fleischhauer; Pietro Crivello
Journal:  Front Immunol       Date:  2018-10-05       Impact factor: 7.561

10.  Unique features and clinical importance of acute alloreactive immune responses.

Authors:  Charlotte F Inman; Suzy A Eldershaw; Joanne E Croudace; Nathaniel J Davies; Archana Sharma-Oates; Tanuja Rai; Hayden Pearce; Mirjana Sirovica; Y L Tracey Chan; Kriti Verma; Jianmin Zuo; Sandeep Nagra; Francesca Kinsella; Jane Nunnick; Rasoul Amel-Kashipaz; Charles Craddock; Ram Malladi; Paul Moss
Journal:  JCI Insight       Date:  2018-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.